Ads
related to: macular degeneration medication warnings chart pdf form
Search results
Results From The WOW.Com Content Network
Anti–vascular endothelial growth factor therapy, also known as anti-VEGF (/ v ɛ dʒ ˈ ɛ f /) therapy or medication, is the use of medications that block vascular endothelial growth factor. This is done in the treatment of certain cancers and in age-related macular degeneration .
The incidence of age-related macular degeneration and its associated features increases with age and is low in people <55 years of age. [101] Smoking is the strongest modifiable risk factor. [102] As of 2008, age-related macular degeneration accounts for more than 54% of all vision loss in the white population in the US. [103]
Pegaptanib [2] sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD). [3] It was discovered by NeXstar Pharmaceuticals (which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States.
Layers of the eye, with the choroid labelled. Choroidal neovascularization (CNV) is the creation of new blood vessels in the choroid layer of the eye.Choroidal neovascularization is a common cause of neovascular degenerative maculopathy (i.e. 'wet' macular degeneration) [1] commonly exacerbated by extreme myopia, malignant myopic degeneration, or age-related developments.
For premium support please call: 800-290-4726 more ways to reach us
Age-Related Macular Degeneration is a degenerative maculopathy associated with progressive sight loss. It is characterised by changes in pigmentation in the Retinal Pigment Epithelium, the appearance of drusen on the retina of the eye and choroidal neovascularization. AMD has two forms; 'dry' or atrophic/non-exudative AMD, and 'wet' or ...